JP7390301B2 - ヒトｐｄ－ｌ２抗体およびその使用方法 - Google Patents

ヒトｐｄ－ｌ２抗体およびその使用方法 Download PDF

Info

Publication number
JP7390301B2
JP7390301B2 JP2020550856A JP2020550856A JP7390301B2 JP 7390301 B2 JP7390301 B2 JP 7390301B2 JP 2020550856 A JP2020550856 A JP 2020550856A JP 2020550856 A JP2020550856 A JP 2020550856A JP 7390301 B2 JP7390301 B2 JP 7390301B2
Authority
JP
Japan
Prior art keywords
antibody
chain variable
fragment
cells
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518415A (ja
JPWO2019182888A5 (https=
JP2021518415A5 (https=
Inventor
マイケル エー． カラン
アシュヴィン アール． ジェイスワル
ドンシン ザ
キ ヴォー
カルロ トニアッティ
ビアンカ プリンツ
ナダカーン ボランド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2021518415A publication Critical patent/JP2021518415A/ja
Publication of JPWO2019182888A5 publication Critical patent/JPWO2019182888A5/ja
Publication of JP2021518415A5 publication Critical patent/JP2021518415A5/ja
Priority to JP2023196493A priority Critical patent/JP7624497B2/ja
Application granted granted Critical
Publication of JP7390301B2 publication Critical patent/JP7390301B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020550856A 2018-03-23 2019-03-15 ヒトｐｄ－ｌ２抗体およびその使用方法 Active JP7390301B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023196493A JP7624497B2 (ja) 2018-03-23 2023-11-20 ヒトｐｄ－ｌ２抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647546P 2018-03-23 2018-03-23
US62/647,546 2018-03-23
PCT/US2019/022444 WO2019182888A1 (en) 2018-03-23 2019-03-15 Human pd-l2 antibodies and methods of use therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023196493A Division JP7624497B2 (ja) 2018-03-23 2023-11-20 ヒトｐｄ－ｌ２抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2021518415A JP2021518415A (ja) 2021-08-02
JPWO2019182888A5 JPWO2019182888A5 (https=) 2022-02-09
JP2021518415A5 JP2021518415A5 (https=) 2022-02-09
JP7390301B2 true JP7390301B2 (ja) 2023-12-01

Family

ID=67987459

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550856A Active JP7390301B2 (ja) 2018-03-23 2019-03-15 ヒトｐｄ－ｌ２抗体およびその使用方法
JP2023196493A Active JP7624497B2 (ja) 2018-03-23 2023-11-20 ヒトｐｄ－ｌ２抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023196493A Active JP7624497B2 (ja) 2018-03-23 2023-11-20 ヒトｐｄ－ｌ２抗体およびその使用方法

Country Status (7)

Country Link
US (3) US11976128B2 (https=)
EP (1) EP3768298A4 (https=)
JP (2) JP7390301B2 (https=)
CN (2) CN119101158A (https=)
AU (2) AU2019239620B2 (https=)
CA (1) CA3092695A1 (https=)
WO (1) WO2019182888A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
CN119101158A (zh) * 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN120693348A (zh) * 2023-02-04 2025-09-23 玛布树生物股份公司 人抗pd-l2抗体及其用途
JP2026506269A (ja) * 2023-09-17 2026-02-24 ジー イェン バイオメディカル カンパニー リミテッド 組換え抗体及びその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505639A (ja) 2004-06-30 2008-02-28 メイヨー ファウンデイション フォー メディカル エデュケイション アンド リサーチ Ｂ７−ｄｃ結合抗体
WO2017053250A1 (en) 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20040131613A1 (en) 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
CL2008001071A1 (es) 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
TW200927761A (en) * 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
US9044457B2 (en) * 2010-06-16 2015-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-DR4 agonist antibodies
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
JP6403166B2 (ja) * 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
KR20220062143A (ko) 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016160792A1 (en) 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
EP3390454B1 (en) 2015-12-17 2026-02-04 University of Maryland, Baltimore County A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
KR20180130541A (ko) * 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
WO2017200796A1 (en) 2016-05-17 2017-11-23 Albert Einstein College Of Medicine, Inc. Engineered pd-1 variants
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN106957823A (zh) 2016-12-28 2017-07-18 无锡傲锐东源生物科技有限公司 抗pd‑l2蛋白单克隆抗体及其用途
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
CN119101158A (zh) * 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505639A (ja) 2004-06-30 2008-02-28 メイヨー ファウンデイション フォー メディカル エデュケイション アンド リサーチ Ｂ７−ｄｃ結合抗体
WO2017053250A1 (en) 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof

Also Published As

Publication number Publication date
EP3768298A1 (en) 2021-01-27
JP7624497B2 (ja) 2025-01-30
US20230174661A1 (en) 2023-06-08
CN119101158A (zh) 2024-12-10
US11976128B2 (en) 2024-05-07
CA3092695A1 (en) 2019-09-26
CN111902156B (zh) 2024-11-08
AU2019239620A1 (en) 2020-09-10
WO2019182888A1 (en) 2019-09-26
CN111902156A (zh) 2020-11-06
US12428489B2 (en) 2025-09-30
US20240270867A1 (en) 2024-08-15
AU2019239620B2 (en) 2026-01-08
JP2021518415A (ja) 2021-08-02
WO2019182888A9 (en) 2020-11-12
JP2024026122A (ja) 2024-02-28
EP3768298A4 (en) 2021-12-08
AU2026202554A1 (en) 2026-04-23
US20260008866A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
JP7390301B2 (ja) ヒトｐｄ－ｌ２抗体およびその使用方法
US12325747B2 (en) Human PD-L1 antibodies and methods of use therefor
JP7713995B2 (ja) ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法
US20250129167A1 (en) Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
HK40119765A (zh) 针对人pd-l1和pd-l2的双特异性抗体及其使用方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231120

R150 Certificate of patent or registration of utility model

Ref document number: 7390301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150